SCHEMBL398849

SCHEMBL398849

CCOC(=O)c1ccc(O)c(C(=O)O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.70
CA1 P00915 7/20 0.70
CA2 P00918 7/20 0.70
CA7 P43166 7/20 0.70
CA9 Q16790 7/20 0.70
CA14 Q9ULX7 7/20 0.70
HSD17B2 P37059 1/20 0.62
ESR1 P03372 1/20 0.56
ESR2 Q92731 1/20 0.56
CSNK2A1 P68400 1/20 0.53
LMNA P02545 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAOA P21397 1/20 0.50
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MCL1 Q07820 1/20 0.47
KLKB1 P03952 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10570974 0.90 CA12 (0.74) CA12CA1CA2CA7CA9
SCHEMBL9252178 0.88 MCL1 (0.62) CA12CA1CA2CA7CA9
SCHEMBL6970075 0.87 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL2292998 0.86 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL403798 0.85 CA1 (0.68) CA12CA1CA2CA7CA9
SCHEMBL8669772 0.85 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL1353933 0.85 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL9136311 0.84 MEN1 (0.62) CA12CA1CA2CA7CA9
SCHEMBL3918302 0.83 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL7013424 0.83 CA12 (0.64) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107935840-B 4-hydroxyisophthalic acid derivative and synthetic method thereof 常州工程职业技术学院 2021-05-25 CN claimed
US-9688807-B2 Epoxy resin system containing polyethylene tetraamines for resin transfer molding processes DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-27 US claimed
EP-2920227-B1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-08 EP claimed
US-9440891-B2 Palladium-catalyzed decarbonylation of fatty acid anhydrides for the production of linear alpha olefins CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2016-09-13 US claimed
EP-2920227-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES Dow Global Technologies LLC (US) 2015-09-23 EP claimed
US-20150240025-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW EUROPE GMBH (CH) 2015-08-27 US claimed
WO-2014078219-A1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW GLOBAL TECHNOLOGIES LLC (US) 2014-05-22 WO claimed
CN-112159347-B Preparation method of picolitamide 常州工程职业技术学院 2022-06-07 CN disclosed
CN-107935840-B 4-hydroxyisophthalic acid derivative and synthetic method thereof 常州工程职业技术学院 2021-05-25 CN disclosed
CN-112159347-A Preparation method of picolitamide 常州工程职业技术学院 2021-01-01 CN disclosed
CN-109305976-A Compound and its application as ACC inhibitor 南京圣和药业股份有限公司 2019-02-05 CN disclosed
US-9688807-B2 Epoxy resin system containing polyethylene tetraamines for resin transfer molding processes DOW GLOBAL TECHNOLOGIES LLC (US) 2017-06-27 US disclosed
EP-2920227-B1 EPOXY RESIN SYSTEM CONTAINING POLYETHYLENE TETRAAMINES FOR RESIN TRANSFER MOLDING PROCESSES DOW GLOBAL TECHNOLOGIES LLC (US) 2017-02-08 EP disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 CN disclosed
US-20020156061-A1 Isophthalic acid derivatives as matrix metalloproteinase inhibitors BARVIAN NICOLE CHANTEL (US) 2002-10-24 US disclosed
WO-2002064547-A2 ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed
US-4442176-A CHROMOGEN, HYDROXYPHTHALIC DIESTER OF SPECIFIED MELTING POINT KAWASAKI KASEI CHEMICALS LTD. (JP) 1984-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156061-A1 Isophthalic acid derivatives as matrix metalloproteinase inhibitors MMP13, MMP1, MMP11 CA12 422/4885CA1 274/4885CA2 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.